1. Home
  2. UTMD vs CRDF Comparison

UTMD vs CRDF Comparison

Compare UTMD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Utah Medical Products Inc.

UTMD

Utah Medical Products Inc.

HOLD

Current Price

$56.07

Market Cap

177.4M

Sector

Health Care

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$2.80

Market Cap

142.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTMD
CRDF
Founded
1978
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.4M
142.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UTMD
CRDF
Price
$56.07
$2.80
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.83
AVG Volume (30 Days)
17.2K
1.1M
Earning Date
01-27-2026
11-06-2025
Dividend Yield
2.18%
N/A
EPS Growth
N/A
N/A
EPS
3.54
N/A
Revenue
$38,633,000.00
$501,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.26
$1.90
52 Week High
$65.56
$4.99

Technical Indicators

Market Signals
Indicator
UTMD
CRDF
Relative Strength Index (RSI) 45.70 60.47
Support Level $55.79 $2.32
Resistance Level $58.23 $3.31
Average True Range (ATR) 1.36 0.17
MACD -0.03 0.03
Stochastic Oscillator 8.89 49.78

Price Performance

Historical Comparison
UTMD
CRDF

About UTMD Utah Medical Products Inc.

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: